WO1997008190A2 - Compounds - Google Patents
Compounds Download PDFInfo
- Publication number
- WO1997008190A2 WO1997008190A2 PCT/EP1996/003731 EP9603731W WO9708190A2 WO 1997008190 A2 WO1997008190 A2 WO 1997008190A2 EP 9603731 W EP9603731 W EP 9603731W WO 9708190 A2 WO9708190 A2 WO 9708190A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- library
- compounds
- selection
- reagents
- molecular weight
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 57
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 16
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims description 38
- 125000001424 substituent group Chemical group 0.000 claims description 30
- 239000003153 chemical reaction reagent Substances 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 10
- 238000004949 mass spectrometry Methods 0.000 claims description 5
- 238000013461 design Methods 0.000 claims description 3
- 238000013507 mapping Methods 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims description 2
- 239000011324 bead Substances 0.000 description 16
- 229920000642 polymer Polymers 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 239000011347 resin Substances 0.000 description 14
- 229920005989 resin Polymers 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 229910052801 chlorine Inorganic materials 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- 125000001309 chloro group Chemical group Cl* 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 235000017168 chlorine Nutrition 0.000 description 7
- 0 CC(C)(C)OC(NCCCC[C@@](C(O)=O)N*)=O Chemical compound CC(C)(C)OC(NCCCC[C@@](C(O)=O)N*)=O 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 150000001805 chlorine compounds Chemical class 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
- BNQRPLGZFADFGA-UHFFFAOYSA-N benzyl(triphenyl)phosphanium Chemical class C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)CC1=CC=CC=C1 BNQRPLGZFADFGA-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000000155 isotopic effect Effects 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 108010016626 Dipeptides Proteins 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- SODQFLRLAOALCF-UHFFFAOYSA-N 1lambda3-bromacyclohexa-1,3,5-triene Chemical compound Br1=CC=CC=C1 SODQFLRLAOALCF-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- 101150117538 Set2 gene Proteins 0.000 description 2
- KQXIHPNFMTYUGI-UHFFFAOYSA-M [3-[[bis[(2-methylpropan-2-yl)oxycarbonyl]amino]methyl]phenyl]methyl-triphenylphosphanium;bromide Chemical compound [Br-].CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)CC1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 KQXIHPNFMTYUGI-UHFFFAOYSA-M 0.000 description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 150000001793 charged compounds Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 150000002668 lysine derivatives Chemical class 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- 150000004714 phosphonium salts Chemical class 0.000 description 2
- 239000000737 potassium alginate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000854350 Enicospilus group Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- MTHDIEPOBSRDIV-ULQDDVLXSA-N His-Met-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CN=CN1 MTHDIEPOBSRDIV-ULQDDVLXSA-N 0.000 description 1
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000001386 capillary affinity electrophoresis Methods 0.000 description 1
- 238000003965 capillary gas chromatography Methods 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000005264 electron capture Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003574 melanophore Anatomy 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- QDQLMNIECVKMHZ-UHFFFAOYSA-N tert-butyl n-[[3-(bromomethyl)phenyl]methyl]-n-[(2-methylpropan-2-yl)oxycarbonyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)CC1=CC=CC(CBr)=C1 QDQLMNIECVKMHZ-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/14—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support
- C40B50/16—Solid phase synthesis, i.e. wherein one or more library building blocks are bound to a solid support during library creation; Particular methods of cleavage from the solid support involving encoding steps
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/00497—Features relating to the solid phase supports
- B01J2219/005—Beads
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00277—Apparatus
- B01J2219/0054—Means for coding or tagging the apparatus or the reagents
- B01J2219/00572—Chemical means
- B01J2219/00581—Mass
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00592—Split-and-pool, mix-and-divide processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00583—Features relative to the processes being carried out
- B01J2219/00596—Solid-phase processes
Definitions
- the present invention relates to combinatorial chemistry, in particular the synthesis of combinatorial libraries which can be used for the identification of bioactive molecules.
- library or “combinatorial library” is meant a collection of individual compounds, each compound having a common core structure wherein the library contains a discrete number of independently variable substituents, functional groups or structural elements, and further, wherein the library is designed so that, for the range of chemical moieties selected for each ofthe independently variable substituents, compounds containing all possible permutations of those substituents will be present in the library.
- a core structure labelled R
- contains three independently variable substituents, labelled X, Y and Z and if X is taken from m different chemical moieties, Y from n different chemical moieties and Z from/? different chemical moieties (wherein m, n and/?
- a typical library will typically contain between 2 to 10000 or more compounds, and often more than 10000 compounds.
- the library can be deconvoluted by an iterative approach, which involves the re-synthesis of mixtures of decreasing complexity until a single compound is identified.
- sub-libraries can themselves be screened. For example if a main library of 100 components is active, 10 sub-libraries of 10 components can be screened. This approach is advantageous since in a sub-library one of the substituents, i.e. the last substituent to be introduced, can be defmed and kept constant. However the approach has the major disadvantage of being time
- a single compound, or relatively small number of compounds, are usually identified which have the desired biological activity. This compound can then serve as a lead for the preparation of further structurally related libraries or single compounds.
- libraries are synthesised on beads
- a collection of beads are usually screened, and if biological activity is detected the single beads are screened and the active compound identified.
- mass spectroscopy can be used to identify compounds from single synthesis beads. For example, Chen et al., J. Amer. Chem. Soc. 116, p. 2661 (1994), and Stankova et al., Drug Dev. Res., 33,p.l46 (1994).
- mass-redundancy a phenomenon known as “mass-redundancy” by which is meant that compounds are indistinguishable on the basis of molecular weight alone. Mass-redundancy may be reduced by measuring molecular weights at higher resolution, when, ultimately, only compounds having identical empirical formulae would be indistinguishable.
- the present invention is based on the principle that each compound in a library will have, by design, a unique molecular weight which can serve as an identifier for that particular compound.
- the invention provides a method for the identification of a biologically active compound, and in particular, the identification of a compound derived from a single biologically active bead.
- the advantages of this method over tagging synthesis beads are firstly the present invention does not impose any restrictions on the nature ofthe chemistry used to synthesise the combinatorial library, since it does not have to be compatible with tagging chemistry and does not introduce additional non-productive synthetic steps, and secondly by using the present invention the compound can, if so required, be identified without association with the bead of origin.
- An additional advantage is the ability to identify the compound by its nominal mass without recourse to high resolution mass spectrometry. Of course, although not necessary for identification, high resolution measurements and analysis of fragmentation patterns remain available options for further confimatory evidence.
- the present invention provides a method for the control of mass redundancies in a combinatorially synthesised compound library which comprises identifying compounds by their molecular weight
- molecular weight is determined by mass spectrometry.
- the above method is used to identify compounds derived from a single bead.
- the present invention allows for the deliberate incorporation ofthe natural isotopic mass patterns of chorine and bromine atoms or other artificially isotopically enriched atoms or molecules, to further extend its scope and usefulness. It will be apparent to those skilled in the art that a structure designed by the method of this invention can be unambiguously characterised by determining its nominal mass and isotope pattern.
- the present invention relies on a selection strategy which is based on the following observation.
- a selection strategy which is based on the following observation.
- Combinatorial libraries may be defined as mixtures of related compounds having a common "core" structure which bears substituent groups (or R-groups) at a number of positions.
- the common core structure might be the peptide backbone, and the varying R-groups would represent the amino acid side-chains.
- the common core structure might be a multiply substituted ring system, for example a para-dianilide, with varying R-groups possibly derived from a range of different acylating agents.
- the above method can be applied to substituent group selection by mapping the nominal molecular weights of available substituent groups onto tables of varying numbers of columns.
- the charts so generated are defined as having a "periodicity" equal to the number of columns. Different charts may be envisaged for different reagent types (e.g. R-COC1, R-NCO).
- the selection of sets of substituent groups must follow the following three rules.
- Rule 1 and Set 2 should be chosen from charts ofthe same periodicity.
- Members of Set 1 should all be chosen from the same column (and be of different masses).
- Members of Set 2 should all be chosen from different columns. It is convenient, although by no means necessary, to map only the varying R-group ofthe reagents, i.e. the R of R-COCl, R-NCO, HO2CH(R)NH2, since the remainder ofthe group adds a constant mass and may be regarded as part ofthe core structure ofthe library. In the case of groups containing Cl and Br, only the lowest isotopic weight (35 or 79 respectively) is used.
- the amino acids make a convenient sized data set to illustrate features ofthe method.
- Set 1 (same column) may contain up to 4 groups,(e.g. Gly, Ser, His, Phe) and Set 2 (different columns) up to 8 (e.g. Gly, Lys, Val, Met, Leu, Asn, Asp, Trp). Hence a total of 32 unique dipeptides could be generated. Ifthe excercise is repeated with a 16 column table, Chart 3 is produced (after simplification).
- Non-peptide libraries are generally non-oligomeric and often consist of a core structure bearing a number of substituent groups.
- substituent groups are derived from sets of similar reagents.
- R 1 and R 2 might be derived from the acid chloride reagents R'COCI and R 2 COCl.
- Chart 4 shows the R-groups of a small selection of acid chlorides mapped to their nominal molecular weights on a periodicity 10 chart, according to the method of this invention. The groups are labelled with their nominal molecular weight suffixed with a letter to distinguish isobaric groups. The use of Chart 4 to select sets of substituents for use in combinatorial libraries is exemplified below.
- Chart 4 shows that up to ten groups of different nominal mass may be selected from column 7, for example, the groups labelled 27a, 57a, 67a, 77a, 87a, 107a, 117a, 127a, 137a, and 147a. Numerous smaller sets could be selected from this and other columns of Chart 4.
- Rule 4 Either, but not both, of Rules 2 and 3 may be replaced by Rules 5 and 6 respectively.
- Rule 7 Exclude groups containing Cl and Br from Sets 1 and 2. Members of Set 3 should be selected freely provided that each member contains different numbers of Cl and Br atoms or other atoms distinguishable by their isotope patterns.
- Rule 7 forces Set 3 to contain mostly halogenated groups.
- the selection rules, Rule 1 to Rule 3 may be represented mathematically.
- the method requires that all numerical values used (molecular weight, periodicity, multiples and remainders) are integer values.
- the periodicity, P corresponds to the number of columns in the graphical method.
- Rule 1 Set 1 and Set 2 are selected using the same value of P in Rule 2 and Rule 3 respectively.
- the invention provides a library synthesised using the above method, rules or algorithm and the use ofthe method, rules or algorithm for the synthesis of a chemical library.
- the polymer-bound lysine derivative from Description 1 (220 mg, 0.15 mmol) was washed with DCM (2x15 ml) and DMF (2x20 ml) then treated with 20% piperidine in DMF (2x20 ml) for 1 and 20 min.
- the resin was washed with DMF (2x15 ml) and DCM (2x15 ml), then treated for 4 hours with triethylamine (0.42 ml, 3 mmol) and one ofthe acid chlorides listed in Table 1 (1.5 mmol) in DCM (15 ml).
- the polymer-bound lysine derivative from Description 2 (140 mg, approx. 0.1 mmol) was washed with DCM (2x15 ml), then treated with 30% trifluoroacetic acid and 2% anisole in DCM (2x15 ml) for 1 and 30 min.
- the resin was washed with DCM (3x15 ml), 10% triethylamine in DCM (2x10 ml), then was treated for 4 h with triethylamine (0.28 ml, 2 mmol) and one of the acid chlorides listed in Table 2 (1 mmol), in DCM (15 ml).
- the resin was washed with DMF (15 ml) and DCM (3x15 ml) and finally methanol (15 ml) to give the title compounds, D3, as fourteen mixtures each often polymer-bound components.
- a suspension of polymer-bound triphenylphosphine prepared from 150-200 um
- the polymer-bound phosphonium salt from Description 4 (385 mg, 0.35 meq) was washed with DCM (2x25 ml), then treated with a mixture of 30% trifluoroacetic acid and 2% anisole in DCM (2x25 ml) for 1 and 30 min.
- the resin was washed with DCM (3x25 ml), 10% triethylamine in DCM (2x25 ml) and DCM (2x25 ml).
- the resin was suspended overnight in a solution of 1 -hydroxy-7-azabenzotriazole (109 mg, 0.8 mmol), 1,3- diisopropylcarbodiimide (0.13 ml, 0.8 mmol) and one ofthe carboxylic acids listed in Table 4 (0.75 mmol) in DMF (10 ml) and DCM (3 ml). After washing with DMF (2x25 ml) and DCM (3x25 ml), the five products were combined as a slurry in DCM, filtered and treated with 20% piperidine in DMF (2x30 ml) for 1 and 30 min. The resin was washed with DMF (2x30 ml) and DCM (3x30 ml), then dried to give the title compounds, D5 (1.83 g, approx 1.75 mmol) as a mixture of five polymer-bound components..
- the polymer-bound phosphonium salt from Description 5 (160 mg, approx 0.17 mmol) was suspended in DCM (10 ml) and treated with triethylamine (0.1 ml, 0.7 mmol) and one ofthe acid chlorides listed in Table 5 (0.35 mmol). After 90 min the resin was filtered and washed with DCM (2x20 ml). The ten products were combined as a slurry in DCM and washed with DMF (3x30 ml) and DCM (2x30 ml). The resin was finally washed successively with 3:1, 1:1 and 1 :3 mixtures of DCM and ether, and then with ether alone to give the title compounds, D6, as a mixture of 50 polymer-bound components.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Structural Engineering (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96930092A EP0852583A2 (en) | 1995-08-30 | 1996-08-23 | Compounds |
JP9509838A JPH11513027A (en) | 1995-08-30 | 1996-08-23 | Compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9517661.6A GB9517661D0 (en) | 1995-08-30 | 1995-08-30 | Novel compounds |
GB9517661.6 | 1995-08-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1997008190A2 true WO1997008190A2 (en) | 1997-03-06 |
WO1997008190A3 WO1997008190A3 (en) | 1997-03-27 |
Family
ID=10779919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1996/003731 WO1997008190A2 (en) | 1995-08-30 | 1996-08-23 | Compounds |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0852583A2 (en) |
JP (1) | JPH11513027A (en) |
GB (1) | GB9517661D0 (en) |
WO (1) | WO1997008190A2 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997037953A1 (en) * | 1996-04-08 | 1997-10-16 | Glaxo Group Ltd. | Mass-based encoding and qualitative analysis of combinatorial libraries |
US5908960A (en) * | 1997-05-07 | 1999-06-01 | Smithkline Beecham Corporation | Compounds |
WO1999035109A1 (en) * | 1998-01-05 | 1999-07-15 | Neogenesis, Inc. | Method for producing mass-coded combinatorial libraries |
US6004823A (en) * | 1997-05-07 | 1999-12-21 | Smithkline Beecham Corporation | Compounds |
WO2001057523A1 (en) * | 2000-02-03 | 2001-08-09 | Nanoscale Combinatorial Synthesis, Inc. | Structure identification methods using mass measurements |
JP2002522598A (en) * | 1998-08-10 | 2002-07-23 | ザ スクリップス リサーチ インスティテュート | Programmable one-pot oligosaccharide synthesis |
WO2002095393A3 (en) * | 2001-05-24 | 2003-05-22 | Ca Nat Research Council | Drug evolution: drug design at hot spots |
US6576472B1 (en) | 2000-07-26 | 2003-06-10 | Smithkline Beecham Corporation | Chemical constructs for solution phase chemistry |
US6584411B1 (en) | 2000-07-26 | 2003-06-24 | Smithkline Beecham Corporation | Methods to facilitate the calculation of yields of reaction products |
US6694267B2 (en) | 1998-01-05 | 2004-02-17 | Neogenesis Drug Discovery, Inc. | Method for producing and screening mass-coded combinatorial libraries for drug discovery and target validation |
EP1728776A3 (en) * | 1998-01-05 | 2006-12-13 | Neogenesis, Inc. | Method for identifying a member of a mass-coded combinatorial library |
US8501498B2 (en) | 2004-07-12 | 2013-08-06 | Dh Technologies Development Pte. Ltd. | Mass tags for quantitative analyses |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5288514A (en) * | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
DK0665897T3 (en) * | 1992-10-01 | 2003-10-20 | Univ Columbia | Complex, combinatorial, chemical libraries encoded with labels |
GB9315847D0 (en) * | 1993-07-30 | 1993-09-15 | Isis Innovation | Tag reagent and assay method |
WO1995019359A1 (en) * | 1994-01-12 | 1995-07-20 | Massachusetts Institute Of Technology | Process for making xanthene or cubane based compounds, and protease inhibitors |
-
1995
- 1995-08-30 GB GBGB9517661.6A patent/GB9517661D0/en active Pending
-
1996
- 1996-08-23 WO PCT/EP1996/003731 patent/WO1997008190A2/en not_active Application Discontinuation
- 1996-08-23 EP EP96930092A patent/EP0852583A2/en not_active Withdrawn
- 1996-08-23 JP JP9509838A patent/JPH11513027A/en active Pending
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997037953A1 (en) * | 1996-04-08 | 1997-10-16 | Glaxo Group Ltd. | Mass-based encoding and qualitative analysis of combinatorial libraries |
US6475807B1 (en) | 1996-04-08 | 2002-11-05 | Smithkline Beecham Corporation | Mass-based encoding and qualitative analysis of combinatorial libraries |
US5908960A (en) * | 1997-05-07 | 1999-06-01 | Smithkline Beecham Corporation | Compounds |
US6004823A (en) * | 1997-05-07 | 1999-12-21 | Smithkline Beecham Corporation | Compounds |
US6207861B1 (en) | 1998-01-05 | 2001-03-27 | Neogenesis, Inc. | Method for producing and screening mass coded combinatorial libraries for drug discovery and target validation |
EP1728776A3 (en) * | 1998-01-05 | 2006-12-13 | Neogenesis, Inc. | Method for identifying a member of a mass-coded combinatorial library |
JP2002500205A (en) * | 1998-01-05 | 2002-01-08 | ネオジェネシス・インコーポレーテッド | Method for producing mass-encoded combinatorial libraries |
WO1999035109A1 (en) * | 1998-01-05 | 1999-07-15 | Neogenesis, Inc. | Method for producing mass-coded combinatorial libraries |
JP2011039067A (en) * | 1998-01-05 | 2011-02-24 | Neogenesis Inc | Manufacturing method of mass coded combinatorial library |
EP2241541A1 (en) * | 1998-01-05 | 2010-10-20 | Neogenesis, Inc. | Method for identifying a member of a mass-coded combinatorial library |
EP2241542A1 (en) * | 1998-01-05 | 2010-10-20 | Neogenesis, Inc. | Apparatus for producing mass-coded combinatorial libraries |
US7169563B2 (en) | 1998-01-05 | 2007-01-30 | Schering Corporation | Method for producing and screening mass-coded combinatorial libraries for drug discovery and target validation |
US6694267B2 (en) | 1998-01-05 | 2004-02-17 | Neogenesis Drug Discovery, Inc. | Method for producing and screening mass-coded combinatorial libraries for drug discovery and target validation |
US6714875B1 (en) | 1998-01-05 | 2004-03-30 | Neogenesis Drug Discovery, Inc. | Method for producing and screening mass-coded combinatorial libraries for drug discovery and target validation |
US6721665B2 (en) | 1998-01-05 | 2004-04-13 | Neogenesis Drug Discovery, Inc. | Method for producing and screening mass-coded combinatorial libraries for drug discovery and target validation |
JP2002522598A (en) * | 1998-08-10 | 2002-07-23 | ザ スクリップス リサーチ インスティテュート | Programmable one-pot oligosaccharide synthesis |
WO2001057523A1 (en) * | 2000-02-03 | 2001-08-09 | Nanoscale Combinatorial Synthesis, Inc. | Structure identification methods using mass measurements |
US6625546B2 (en) | 2000-02-03 | 2003-09-23 | Nanoscale Combinatorial Synthesis, Inc. | Structure identification methods using mass measurements |
US6584411B1 (en) | 2000-07-26 | 2003-06-24 | Smithkline Beecham Corporation | Methods to facilitate the calculation of yields of reaction products |
US6576472B1 (en) | 2000-07-26 | 2003-06-10 | Smithkline Beecham Corporation | Chemical constructs for solution phase chemistry |
WO2002095393A3 (en) * | 2001-05-24 | 2003-05-22 | Ca Nat Research Council | Drug evolution: drug design at hot spots |
US8501498B2 (en) | 2004-07-12 | 2013-08-06 | Dh Technologies Development Pte. Ltd. | Mass tags for quantitative analyses |
Also Published As
Publication number | Publication date |
---|---|
JPH11513027A (en) | 1999-11-09 |
EP0852583A2 (en) | 1998-07-15 |
GB9517661D0 (en) | 1995-11-01 |
WO1997008190A3 (en) | 1997-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lebl et al. | One‐bead–one‐structure combinatorial libraries | |
Lowe | Combinatorial chemistry | |
US5541061A (en) | Methods for screening factorial chemical libraries | |
EP0863858B1 (en) | Mass-based encoding and qualitative analysis of combinatorial libraries | |
US6416949B1 (en) | Method of synthesizing diverse collections of oligomers | |
US20030100018A1 (en) | Mass-based encoding and qualitative analysis of combinatorial libraries | |
WO1997008190A2 (en) | Compounds | |
US20030182068A1 (en) | Device and methods for directed synthesis of chemical libraries | |
AU2292695A (en) | Complex combinatorial chemical libraries encoded with tags | |
EP0763202A1 (en) | Encoded combinatorial libraries | |
Frank | High-density synthetic peptide microarrays: emerging tools for functional genomics and proteomics | |
WO1994013623A1 (en) | Synthesis of encoded polymers | |
WO1999035109A1 (en) | Method for producing mass-coded combinatorial libraries | |
Williard et al. | Combinatorial chemistry: a rational approach to chemical diversity | |
JP2011039067A (en) | Manufacturing method of mass coded combinatorial library | |
US20010007740A1 (en) | Intrinsically labelled solid support | |
WO1996023749A1 (en) | Chemical libraries, labelling and deconvolution thereof | |
Southern | High-density gridding: techniques and applications | |
CA2367541A1 (en) | Encoding scheme for solid phase chemical libraries | |
Lebl et al. | Felder zyxwvutsrqponmlkj | |
Ambre et al. | Combinatorial Chemistry: Role in Lead Discovery | |
EP1728776A2 (en) | Method for identifying a member of a mass-coded combinatorial library | |
NANDAN et al. | PREMLATA K. AMBRE, ANISH N. GOMATAM | |
Hultschig | Two-dimensional screening: towards establishing a novel technique to study biomolecular interactions | |
Ferguson | Design, synthesis and biological screening of combinatorial chemical libraries |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996930092 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1997 509838 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1996930092 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996930092 Country of ref document: EP |